| |
Case without ulcer
|
Case with ulcer
| |
Adjusted OR
|
|---|
|
Medicine
|
n = 212 (%)
|
n = 14 (%)
|
OR (95% CI)*
|
(95% CI)**
|
|---|
|
Anticoagulanta
|
19
|
(9.0)
|
4
|
(28.6)
|
4.06
|
(1.16 − 14.21)
|
5.88
|
(1.19 − 28.99)
|
|
Other antiplateletb
|
49
|
(23.1)
|
1
|
(7.1)
|
0.26
|
(0.03 − 2.01)
|
0.20
|
(0.02 − 1.83)
|
|
PPIc
|
89
|
(42.0)
|
2
|
(14.3)
|
0.23
|
(0.05 − 1.05)
|
0.13
|
(0.02 − 0.73)
|
|
H2RAd
|
36
|
(17.0)
|
1
|
(7.1)
|
0.38
|
(0.05 − 2.97)
|
0.35
|
(0.04 − 3.20)
|
|
Ca-blockere
|
67
|
(31.6)
|
4
|
(28.6)
|
0.87
|
(0.26 − 2.86)
|
1.27
|
(0.32 − 5.14)
|
|
ARBf
|
99
|
(46.7)
|
5
|
(35.7)
|
0.63
|
(0.21 − 1.96)
|
0.45
|
(0.12 − 1.65)
|
|
ACE inhibitorg
|
17
|
(8.0)
|
1
|
(7.1)
|
0.88
|
(0.11 − 7.16)
|
0.39
|
(0.05 − 4.34)
|
|
HMG-Co A redactase inhibitorh
|
94
|
(44.3)
|
6
|
(42.9)
|
0.94
|
(0.32 − 2.81)
|
2.09
|
(0.53 − 8.29)
|
|
NSAIDi
|
9
|
(4.3)
|
2
|
(14.3)
|
3.76
|
(0.73 − 19.36)
|
6.48
|
(0.75 − 56.41)
|
- OR, odds ratio; CI, confidence interval; PPI, proton pump inhibitor; H2RA, H2-receptor antagonist; ARB, AT1-receptor blocker; ACE, angiotensin-converting enzyme; HMG-Co A, 3-hydroxy-3-methyglutaryl coenzyme A, NSAID, non-steroidal anti-inflammatory drug.
- *Univariate analysis; ** Multivariate analysis adjusted for age and sex.
- aWarfarin 1 − 5 mg/day, bTiclopidine 100 or 200 mg/day, clopidogrel 75 mg/day, cilostazol 200 mg/day, cOmeprazole 10 or 20 mg/day, lansoprazole 15 or 30 mg/day, rabeprazole 10 mg/day, dFamotidine 10 or 20 or 40 mg/day, ranitidine 150 mg/day, roxatidine 150 mg/day, lafutidine 10 mg/day, eNifedipine 20 or 40 mg/day, amlodipine 2.5 or 5 mg/day, fCandesartan 4 or 8 mg/day, telmisartan 40 mg/day, olmesartan 20 mg/day, gImidapril 5 mg/day, hPravastatin 10 mg/day, atorvastatin 10 mg/day, iLoxoprofen 60 or 120 or 180 mg/day, selecoxib 100 mg/day, naproxen 300 mg/day.
